{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:03:25Z","timestamp":1765976605468,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>This is the first reported case of a patient with dilated cardiomyopathy (DCM) and severely impaired left ventricular function to receive a combined treatment of granulocyte colony-stimulating factor therapy and an intracoronary delivery of autologous bone marrow-derived mononuclear cells with percutaneous circulatory assistance (the Impella CP device; Abiomed, Danvers, MA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main symptoms and outcome<\/jats:title><jats:p>Three months post-treatment, the gentleman in his early 70s demonstrated an improvement in left ventricular ejection fraction (13\u201317%) and a reduction in New York Heart Association class from III to class I. There was also an improvement in his 6-minute walk test (147\u2013357 meters), N-terminal pro-brain natriuretic peptide level (14,099\u20137,129 ng\/l) and quality of life scores. There were no safety concerns during the treatment or follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case report suggests combined cell and cytokine therapy with adjunctive circulatory support could be a safe and promising treatment for patients with DCM and severely reduced ejection fraction.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.1002508","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T07:18:55Z","timestamp":1662967135000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: Cytokine therapy and an intracoronary autologous bone marrow-derived cell infusion with Impella support in a patient with dilated cardiomyopathy and a severely reduced ejection fraction"],"prefix":"10.3389","volume":"9","author":[{"given":"Russell Charles","family":"Hall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohini","family":"Ramaseshan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/0002-9149(92)90901-A","article-title":"Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute Workshop)","volume":"69","author":"Harlan","year":"1992","journal-title":"Am J Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.healun.2009.08.005","article-title":"Scientific registry of the international society for heart and lung transplantation: introduction to the 2009 annual reports","volume":"28","author":"Hertz","year":"2009","journal-title":"J Hear Lung Transplant."},{"key":"B3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(16)31713-5","article-title":"Dilated cardiomyopathy","volume":"390","author":"Weintraub","year":"2017","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1053\/euhj.2002.3255","article-title":"Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population","volume":"23","author":"Hobbs","year":"2002","journal-title":"Eur Heart J."},{"key":"B5","article-title":"Cell-based regenerative therapy","volume-title":"The PCR-EAPCI Textbook","author":"Reid","year":"2021"},{"key":"B6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.cardfail.2010.11.007","article-title":"Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy","volume":"17","author":"Vrtovec","year":"2011","journal-title":"J Card Fail."},{"key":"B7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1161\/CIRCRESAHA.112.276519","article-title":"Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up","volume":"112","author":"Vrtovec","year":"2013","journal-title":"Circ Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cardfail.2014.11.005","article-title":"Intracoronary transplantation of CD34+ cells is associated with improved myocardial perfusion in patients with nonischemic dilated cardiomyopathy","volume":"21","author":"Lezaic","year":"2015","journal-title":"J Card Fail."},{"key":"B9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.5966\/sctm.2015-0172","article-title":"Efficacy of CD34 + stem cell therapy in nonischemic dilated cardiomyopathy is absent in patients with diabetes but preserved in patients with insulin resistance","volume":"5","author":"Vrtovec","year":"2016","journal-title":"Stem Cells Transl Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1161\/CIRCRESAHA.117.312170","article-title":"Effects of repetitive transendocardial CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy","volume":"123","author":"Vrtovec","year":"2018","journal-title":"Circ Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijcard.2008.06.002","article-title":"Granulocyte-colony stimulating factor or granulocyte-colony stimulating factor associated to stem cell intracoronary infusion effects in non-ischemic refractory heart failure","volume":"138","author":"Bocchi","year":"2010","journal-title":"Int J Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1093\/eurheartj\/ehv390","article-title":"Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial","volume":"36","author":"Hamshere","year":"2015","journal-title":"Eur Heart J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"CD007888","DOI":"10.1002\/14651858.CD007888.pub3","article-title":"Stem cell therapy for chronic ischaemic heart disease and congestive heart failure","volume":"12","author":"Fisher","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.3390\/jcm11113205","article-title":"Meta-analysis of percutaneous endomyocardial cell therapy in patients with ischemic heart failure by combination of individual patient data (IPD) of ACCRUE and publication-based aggregate data","volume":"11","author":"Gy\u00f6ngy\u00f6si","year":"2022","journal-title":"J Clin Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/ccd.21160","article-title":"Effects of left ventricular unloading by Impella recover LP2.5 on coronary hemodynamics","volume":"70","author":"Remmelink","year":"2007","journal-title":"Catheter Cardiovasc Interv."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1161\/CIRCULATIONAHA.112.098194","article-title":"A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study","volume":"126","author":"O'Neill","year":"2012","journal-title":"Circulation."},{"key":"B17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.repc.2017.05.013","article-title":"The role of Impella in high-risk percutaneous coronary intervention","volume":"37","author":"Moura-Ferreira","year":"2018","journal-title":"Rev Port Cardiol (Engl Ed)."},{"key":"B18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1055\/s-2003-45422","article-title":"Initial experiences with the Impella device in patients with cardiogenic shock - Impella support for cardiogenic shock","volume":"51","author":"Meyns","year":"2003","journal-title":"Thorac Cardiovasc Surg."},{"key":"B19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2217\/rme-2018-0121","article-title":"Circulatory support and stem cell therapy in the management of advanced heart failure: a concise review of available evidence","volume":"14","author":"Hussain","year":"2019","journal-title":"Regen Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"10344","DOI":"10.1073\/pnas.181177898","article-title":"Mobilized bone marrow cells repair the infarcted heart, improving function and survival","volume":"98","author":"Orlic","year":"2001","journal-title":"Proc Natl Acad Sci USA."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1161\/01.CIR.0000129770.93985.3E","article-title":"Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodelling by postinfarction granulocyte colony-stimulating factor treatment","volume":"109","author":"Minatoguchi","year":"2004","journal-title":"Circulation."},{"key":"B22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/nm1199","article-title":"G-CSF prevents cardiac remodelling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes","volume":"11","author":"Harada","year":"2005","journal-title":"Nat Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/labinvest.3700367","article-title":"Treatment with granulocyte colony-stimulating factor ameliorates chronic heart failure","volume":"86","author":"Li","year":"2006","journal-title":"Lab Investig."},{"key":"B24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1089\/scd.2012.0139","article-title":"The effects of age, disease state, and granulocyte colony-stimulating factor on progenitor cell count and function in patients undergoing cell therapy for cardiac disease","volume":"22","author":"Mozid","year":"2013","journal-title":"Stem Cells Dev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.amjcard.2020.10.056","article-title":"Analysis of adverse events related to Impella usage (from the manufacturer and user facility device experience and national inpatient sample databases)","volume":"140","author":"Philipson","year":"2021","journal-title":"Am J Cardiol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1002508\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T07:18:59Z","timestamp":1662967139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1002508\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":25,"alternative-id":["10.3389\/fcvm.2022.1002508"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.1002508","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"article-number":"1002508"}}